Analysis: Antibiotics Crisis Prompts Rethink on Risks, Rewards

by | Mar 19, 2013 | Health

Today, as the world confronts another crisis, this time one of antibiotic resistance, the industry is doing the opposite. It is cutting research in a field that offers little scope for making money.

Antibiotics have become victims of their own success. Seen as cheap, routine treatments, they are overprescribed and taken haphazardly, creating “superbugs” they can no longer fight.

These “superbugs” are growing, but are not yet widespread, so the costly research needed to combat them is not worthwhile. Medical experts say this dilemma could return medicine to an era before Alexander Fleming discovered penicillin in 1928.

Fixing the problem will need both faster approval of last-resort drugs and new ways to guarantee rewards for companies, according to both industry leaders and public health officials who have been sounding the alarm.

Paul Stoffels, pharmaceuticals head at Johnson & Johnson, is better placed than many to understand the problems.

His company offered a rare glimmer of hope in December when it won regulatory approval for a new treatment for drug-resistant tuberculosis – a growing issue in many countries.

Unfortunately for the world, it was a one-off and J&J is not currently developing any more antibiotics.

“The market for a new antibiotic is very small, the rewards are not there and so the capital is not flowing,” he said in an interview in London.

“It’s about the sheer amount of money people are prepared to pay for a drug. In cancer, people pay $30,000, $50,000 or $80,000 (per patient) for a drug, but for an antibiotic it is likely to be only a few hundred dollars.”

On Monday, AstraZeneca, facing tough decisions about where to invest, said it would put less money in developing anti-infectives. “We have to make choices and we have to focus our investments where we think we can make a substantial difference,” CEO Pascal Soriot told Reuters.

The regulatory bar for drug approval is a key consideration for any company weighing R&D investment.

For antibiotics is very high, partly due to a scandal over the approval of Sanofi’s drug Ketek in 2004, which U.S. officials said later should be reserved for serious diseases due to the risk of side effects.

The head U.S. Food and Drug Administration’s (FDA) drugs wing, Janet Woodcock, last year pledged a complete “reboot” of the approval process, aware of the stifling effect recent official caution has had on the development of new drugs.

The rapid approval of J&J’s tuberculosis drug in December, based only on mid-stage Phase II data, may be a sign of a new flexibility at the FDA, which matters because the United States is the world’s biggest drugs market.

The Generating Antibiotic Incentives Now (GAIN) Act, which came into effect in the U.S. last October, will also help by offering an extra five years of market exclusivity.

Still, the Infectious Diseases Society of America (IDSA)believes more legislation is needed to set out a clear path by which new antibiotics can be approved for a limited population after much smaller and faster clinical trials.

Just as in the early years of HIV, it argues, the world must accept riskier new drugs for incurable infections when there are no alternatives and patients’ lives are on the line.

The European Medicines Agency is also working on new rules to encourage antibiotic development, while the European Union last year launched a novel public-private partnership to get governments and companies to share information and funding.

Fee Instead of Price

Such public-private alliances across countries could start to change the conventional market model, according to Andrew Witty, CEO of GlaxoSmithKline, another of the few Big Pharma companies still actively researching antibiotics.

He favors greater sharing of research and has made an offer to England’s chief medical officer Sally Davies to create new laboratories for developing research ideas brought in by others.

“I’m pretty sure that a classic model isn’t going to solve this question and we need to be much more creative,” Witty said.

New market approaches could include doing away with a price and instead having the healthcare system paying the inventor a fee per year as a reward for delivering a medicine, he said.

In some years, society would end up paying more in fees than it would in drug bills; in other years less. But at least companies would have an assured revenue stream.

Healthcare officials on both sides of the Atlantic are showing a willingness to do things differently after drawing attention to the antibiotic crisis this month.

Davies said the steady rise in resistance in the last five years represented a “ticking time bomb” that ranks alongside terrorism as a threat to the nation. Tom Frieden, director of the U.S. Centers for Disease Control and Prevention, called for an urgent fight-back against “nightmare bacteria”.

Rush for Exit

The rush for the exit on antibiotic research has been dramatic.

Pfizer, once the leader in the field, closed its antibiotic R&D centre in Connecticut in 2011, to the dismay of many scientists. It now focuses anti-bacterial work on vaccines.

Others to have quit include Roche, Bristol-Myers Squibb and Eli Lilly, leaving only a handful of firms like GlaxoSmithKline, AstraZeneca and Merck & Co in the game. With basic research providing few new leads for drug targets, they are finding it tough.

Some smaller companies like Cubist Pharmaceuticals, Forest Laboratories, The Medicines Company and Optimer Pharmaceuticals are also active, hoping to capitalize on a niche left vacant by Big Pharma.

But Robert Guidos, public policy expert at the IDSA, fears minnows will struggle.

“Small companies rely on larger companies to help them get through Phase II and Phase III clinical development because it is so expensive,” he said.

“The fewer large companies you have, the less help the smaller ones get and, as a result, few of the antibiotics now in early development are likely to make it across the finish line.”

Since the 1980s, the number of new systemic antibiotics approved by the FDA has plunged from 16 in 1983-87 to just two in the last five years, according to the IDSA.

In the meantime, the “superbugs” are on the increase.

One of the best known is methicillin-resistant Staphylococcus aureus, or MRSA, which alone is estimated to kill some 20,000 people every year in the United States – far more than AIDS – and a similar number in Europe.

Others are spreading. Cases of totally drug resistant tuberculosis have appeared in recent years, as have untreatable strains of gonorrhea, and a new wave of “super superbugs” with a mutation called New Delhi metallo-beta-lactamase (NDM 1), first seen in India, has now turned up across the globe.

As head of the company that developed AZT, the first HIV drug, GSK’s Witty thinks the antibiotic problem can be cracked, given sufficient political will – but it won’t happen overnight.

“This is a long cycle time business. Even if we get this absolutely brilliantly tuned up it is going to be a five to 10 year journey,” he said.

CHARISMA NEWSLETTERS

Stay up-to-date with current issues, Christian teachings, entertainment news, videos & more.

The latest breaking Christian news you need to know about as soon as it happens.

Prophetic messages from respected leaders & news of how God is moving throughout the world. 


MORE FROM CHARISMA

How Would an Encounter in Heaven Transform Your Life?

How Would an Encounter in Heaven Transform Your Life?

Have you ever wondered what heaven was like? What does a person see and experience when they are in heaven? Is the arrival in immediate when a believer dies? These are great questions and ones that Rabbi Felix Halpern can answer. A mix-up in medicine brought about a...

Prophet: Learning to Listen With Discernment

Prophet: Learning to Listen With Discernment

Learning to listen with discernment means that you begin to recognize the voice of God so well that other voices sound unfamiliar. In John 10:5a, Jesus told his followers, "Yet they will never follow a stranger." This statement needs to become a reality in your life....

5 Stages of Building a Successful Team

5 Stages of Building a Successful Team

The definition and purpose of leadership are directly tied to organizational models and the five stages of building an organizational model. Let’s talk about those five stages. What we say here may sound somewhat like what you may have heard before about building a...

Mario Murillo Compares America Now to Israel on Mount Carmel

Mario Murillo Compares America Now to Israel on Mount Carmel

America stands in a crucial moment, much like the moment where Elijah made Israel choose between Baal and Jehovah. Elijah said to the people, "How long do you halt between two opinions? If Baal is God..." That's according to Evangelist Mario Murillo, whose ministry...

Spirit-Filled Pastor: Can I Ask God for Confirmation?

Spirit-Filled Pastor: Can I Ask God for Confirmation?

There are many incidents of God giving people a sign throughout the Bible. Although I believe God still does this, I also believe that we must be careful. Asking for a sign can be misleading if other factors are not taken into consideration. In Genesis, we find an...

Man Who Spent 23 Minutes in Hell: Are You Ready To Meet Jesus?

Man Who Spent 23 Minutes in Hell: Are You Ready To Meet Jesus?

The last words Jesus spoke to me in my 23 Minutes In Hell vision were, “Tell them I am coming very, very soon.” Then He repeated Himself and said again, “Tell them I am coming very, very soon.” The Bible is clear that Jesus is coming back to rapture His believers,...

RECENT ARTICLES

The Best Way to Love Others and Yourself

I believe that other than the gospel regarding salvation through faith in Christ, learning to walk in love is the most important lesson in God’s Word. Jesus says that love is the most important...
10 Reasons the Apostolic Movement Is Essential to Gospel Expansion

10 Reasons the Apostolic Movement Is Essential to Gospel Expansion

The global apostolic movement is the most significant expression of Christianity today. This is the view expressed by historian Philip Jenkins. He talks about the rapid expansion of the church in the global south, much of which is reminiscent of the first-century...

Experience a Better Kind of Love in Your Relationships

Experience a Better Kind of Love in Your Relationships

Do you have any relationship struggles? Perhaps you want to learn how to love, for real. Too often today, people search for a fairytale love and are disappointed when the fairytale fizzles, which it will. Michael Gibson, author of Real Life Love, challenges folks to...

The Roaring Heart Podcast with Anthony Hart

The Roaring Heart Podcast with Anthony Hart

The Roaring Heart Podcast With Anthony Hart The Roaring Heart Podcast is a prophetic podcast reflecting the heart of the Holy Spirit in people. It’s a unique mix of interviews, prophetic declarations, prayers, heartfelt monologues, spoken word excerpts, and soaking...

The Power of Godly Words Over Another Life—and Yours

The Power of Godly Words Over Another Life—and Yours

Have the words that others have spoken over you ever significantly impacted you? Words can birth destinies on the inside of us and bring hope to our hearts for the future. They have the power to ignite our dreams and give life to our souls. At the same time, negative...

How You Can Foil the Plot Against Your Life

How You Can Foil the Plot Against Your Life

“The thief comes only to steal and kill and destroy; I came that they may have life, and have it abundantly.” Jesus warned us that we have an enemy, and he is a thief. He steals our joy, purpose, peace and, if he can, our future. Jesus knew it was important to warn us...

Activating Introverts in Evangelism

Activating Introverts in Evangelism

 Many believers mistakenly think that evangelism is only for charismatic, extroverted personality types. If they aren’t called to be evangelists, they shrink back from sharing the gospel with the lost entirely. The scriptural reality is that fivefold ministers, and...

Pin It on Pinterest

[class^="wpforms-"]
[class^="wpforms-"]